Novo Nordisk A/S

NYSE:NVO Stock Report

Market Cap: US$554.5b

Novo Nordisk Future Growth

Future criteria checks 4/6

Novo Nordisk is forecast to grow earnings and revenue by 14.8% and 13.9% per annum respectively. EPS is expected to grow by 14.7% per annum. Return on equity is forecast to be 84.7% in 3 years.

Key information

14.8%

Earnings growth rate

14.7%

EPS growth rate

Pharmaceuticals earnings growth21.0%
Revenue growth rate13.9%
Future return on equity84.7%
Analyst coverage

Good

Last updated17 Apr 2024

Recent future growth updates

Recent updates

Novo Nordisk: The Moat Won't Last Forever

Apr 09

Shaping The Future Of Obesity Treatment: GLP-1 Agonists At The Forefront

Mar 18

Novo Nordisk: My 'Hold' Thesis For 2024 - The Premium Must Be Justified

Mar 07

Novo Nordisk, A Very Healthy Pharma Stalwart

Feb 28

Novo Nordisk: SOTP After Impressive FY23 And Weight Loss Going Mainstream, Maintain Buy

Feb 23

Novo Nordisk: Irrational Exuberance Isn't Worth The Risk

Feb 16

Novo Nordisk: Outlook For Weight Loss Drugs In 2024

Jan 22

Taking Novo Nordisk To The Next Level

Jan 15

Profiting From Obesity Drugs HRTS, Novo Nordisk And Eli Lilly

Jan 02

Novo Nordisk: Latest Insights Confirm Exceptionally Bullish Opportunity

Dec 12

Novo Nordisk: Eli Lilly's Zepbound Approval Is Not A Threat To Valuation

Nov 24

Novo Nordisk: Growing To Potentially Become The First Trillion-Dollar European Champion

Oct 24

Novo Nordisk: Catching The Falling Knife Now Could Really Hurt

Sep 22

Novo Nordisk: Strong Fundamentals Meet Technical Uptrends

Aug 30

Novo Nordisk: Denmark's Coca-Cola

Jul 25

The Case For Novo Nordisk: Growth, Dividends, And A New Treatment Frontier

Jul 11

Novo Nordisk Is A Hold Despite Explosive Growth In Diabetes And Obesity Care

Jun 23

Novo Nordisk: Dominating In Diabetes And Obesity

Jun 05

Novo Nordisk: Flourishing Financials And Emerging Opportunities In Diabetes And Obesity

May 23

Novo Nordisk: Attractive Market But Likely No Margin Of Safety

Feb 15

Novo Nordisk to sell Wegovy in bigger European markets -- Bloomberg

Feb 07

Novo Nordisk FY 2022 Earnings Preview

Jan 31

Novo Nordisk says FDA updated label for oral diabetes therapy Rybelsus

Jan 13

Earnings and Revenue Growth Forecasts

NYSE:NVO - Analysts future estimates and past financials data (DKK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2026398,834146,867120,286165,17821
12/31/2025345,587125,14099,159143,31625
12/31/2024287,280103,57664,793124,52925
12/31/2023232,26183,68370,012108,908N/A
9/30/2023214,49075,31277,825106,458N/A
6/30/2023201,32567,23967,49789,731N/A
3/31/2023188,29061,12967,34185,115N/A
12/31/2022176,95455,52564,13478,887N/A
9/30/2022167,19552,82557,87568,769N/A
6/30/2022157,25150,53957,68066,037N/A
3/31/2022149,02749,34459,66567,331N/A
12/31/2021140,80047,75747,61555,000N/A
9/30/2021134,60546,18340,21358,189N/A
6/30/2021129,91044,36231,81454,188N/A
3/31/2021126,87542,86431,33753,194N/A
12/31/2020126,94642,13829,87051,951N/A
9/30/2020127,22541,53744,80056,944N/A
6/30/2020126,57541,43347,62156,126N/A
3/31/2020126,60540,40336,98746,904N/A
12/31/2019122,02138,95135,55146,782N/A
9/30/2019119,33638,73136,78549,029N/A
6/30/2019116,82137,57431,25143,960N/A
3/31/2019114,19238,32232,20244,691N/A
12/31/2018111,83138,62832,20644,616N/A
9/30/2018110,09138,38431,57643,236N/A
6/30/2018108,94339,11733,78744,538N/A
3/31/2018110,17438,72528,99138,885N/A
12/31/2017111,69638,13032,52041,168N/A
9/30/2017113,27638,576N/A46,289N/A
6/30/2017114,19938,609N/A48,557N/A
3/31/2017113,02038,626N/A52,937N/A
12/31/2016111,78037,925N/A48,314N/A
9/30/2016111,08437,484N/A47,280N/A
6/30/2016110,33936,064N/A44,179N/A
3/31/2016109,93934,439N/A41,656N/A
12/31/2015107,92734,860N/A38,287N/A
9/30/2015103,63633,131N/A35,469N/A
6/30/201599,09331,248N/A35,578N/A
3/31/201593,66329,899N/A31,729N/A
12/31/201488,80626,481N/A31,692N/A
9/30/201485,91926,005N/A29,763N/A
6/30/201484,18125,920N/A23,783N/A
3/31/201483,93225,660N/A22,941N/A
12/31/201383,57225,184N/A25,942N/A
9/30/201382,83624,886N/A22,084N/A
6/30/201382,17024,138N/A23,829N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NVO's forecast earnings growth (14.8% per year) is above the savings rate (2.3%).

Earnings vs Market: NVO's earnings (14.8% per year) are forecast to grow faster than the US market (14.6% per year).

High Growth Earnings: NVO's earnings are forecast to grow, but not significantly.

Revenue vs Market: NVO's revenue (13.9% per year) is forecast to grow faster than the US market (8.1% per year).

High Growth Revenue: NVO's revenue (13.9% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: NVO's Return on Equity is forecast to be very high in 3 years time (84.7%).

Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.